United States Food and Drug Administration: FDA Approves First Generic Naloxone Nasal Spray to Treat Opioid Overdose.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-naloxone-nasal-spray-treat-opioid-overdose

has been cited by the following article:

• TITLE: Exploring the Contribution of Pharmacists in Addressing the Opioid Crisis through Naloxone Prescriptions and Pharmacist-Led Interventions

  AUTHORS: Michelle Krey, Sophia Villa, Nadia Gharibyar, Haroon Mesdaq

  KEYWORDS: Naloxone, Narcan, Opioid Crisis, Opioid Epidemic, Pharmacy, Pharmacist, Interventions

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.15 No.2, February 29, 2024

  ABSTRACT: The opioid epidemic in the United States continues to take the lives of many individuals, with overdoses continuing to rise every year. Naloxone is an opioid antagonist that is efficacious in temporarily reversing opioid overdoses. Pharmacists play an important role in the accessibility and education of naloxone in both the community and health system settings. Recent efforts, such as co-dispensing naloxone with opioid prescriptions, naloxone training programs, and approval of naloxone to be over-the-counter, have been implemented in hopes to better control the opioid epidemic. Despite the efforts to make naloxone more accessible, there are still some barriers to overcome such as lack of training, cost, stigma, and patient refusal. This review aims to explore the contributions pharmacists have made thus far and define the barriers that still have to be resolved.